Contact

Write to Us

    Your Name (required)

    Your Email (required)

    Subject

    Your Message

    Contact Us

    Matrix II, unit 1.10
    Science Park 400
    1098 XH Amsterdam
    The Netherlands

    Email: info@panaxea.eu

    Phone No: +31 20 7400 778

    Follow Us on Twitter

    April 20, 2015

    Long-term cost–effectiveness of Oncotype DX® versus current clinical practice from a Dutch cost perspective

    Michelle Kip, Helma Monteban & Lotte Steuten, Long-term cost–effectiveness of Oncotype DX® versus current clinical practice from a Dutch cost perspective, Journal of Comparative Effectiveness Research. Link to publication
    March 31, 2015
    Panaxea Courses

    Courses

    Building upon our expertise and experience, Panaxea can organize or contribute to courses, seminars and workshops on a wide range of topics in the field of health technology assessment. For this, we can build on years of experience in teaching to students of the University of Twente. In particular, Panaxea […]
    March 31, 2015

    Introduction course to early Health Technology Assessment by Panaxea

    Panaxea has cooperated with the University of Twente department Health Technology and Services Research in developing a one-day introductory course to early health technology assessment.
    March 5, 2015

    Maarten IJzerman nominated President-elect ISPOR

    The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a member-driven organization led by a diverse Board of Directors and professional staff who work collaboratively to ensure the organization is strategically positioned and effectively serving its membership. The election for the 2015-2016 ISPOR Board of Directors and President-elect is […]
    February 25, 2015

    Systematic literature review

    For a medical device company developing blood glucose meters, we performed a systematic literature review on self-monitoring of blood glucose levels among patients with type 2 diabetes. The report covered an analysis of the burden of the disease and the cost-effectiveness of blood glucose self-monitoring. Cost tables, specifying the cost […]
    February 25, 2015
    Cost effective health model

    Market access and reimbursement report

    A medical device company has developed a new technology that could improve the visualization and treatment of the affected heart tissue during catheter ablations of the left atrium of the heart. They were interested in getting an overview of the market access and reimbursement regulations in the Netherlands and Belgium […]
    February 25, 2015
    Health Technology Assessment

    Cost-effectiveness and budget impact model for a diagnostic test

    Allergic Rhinitis (AR) is a condition where an inflammatory reaction of the immune system is caused by specific allergens. Respiratory AR affects around 15% of the people in the Netherlands. Mostly, AR is treated with symptomatic treatment, but immunotherapy potentially offers a curative treatment by minimizing sensitivity to the allergen. […]
    September 7, 2014

    Panaxea at ISPOR Amsterdam, 10-13 November 2014

    Panaxea will be one of the exhibiting organizations at the 17th Annual ISPOR European Congress in Amsterdam (RAI). Visit our booth #913  
    September 2, 2014

    New office

    Our office has been relocated to a new address! Hengelosestraat 221 7521 AC Enschede The Netherlands  [su_gmap address=”Hengelosestraat 221″]